DETERMINATION OF SALIENT ISSUES
2.A.2 Describe: a) the company's routines for mapping and identifying risk and show how the negative impact was
identified and prioritised in this period: b) eventual aspects of the company that have not been covered in this report
(product groups, own products, departments etc.) and why you not chose to prioritize these in the continued work: c)
how information was gathered, what sources were used, and which stakeholders have been involved/consulted: d)
whether you have identified areas where information is lacking in order to get an overview, and how you are planning
to proceed to collect more information/handle this.
As mentioned earlier in this report, Mediq Own Brand products are manufactured by our sister company,
Medeco, in the Mediq Group. Medeco is the legal Manufacturer of these products and the production is
outsourced to strategic manufacturing partners. Medeco follows the same framework as the Mediq Group, based
on our common Code of Conduct.
In order to have close control of the contracted manufacturers Medeco are member of Amfori BSCI, a leading
global business association for open and sustainable trade.
Amfori creates a platform which actively monitors and shares supply chain information to ensure transparent
and sustainable trade. They provide a network of independent, accredited audit companies that monitor and
evaluate factories according to the eleven BSCI principles. When not available via Amfori, Medeco audits
factories with an independent third party. Medeco performs annual due diligence on the social performance and
improvement planning of the manufacturing partners. The outcome is monitored and tracked by the
management, and when required, supplemental actions are initiated. The information is shared with our Nordic
Sourcing department, and in this way part of Responsible Sourcing program for the Nordic Cluster.
In addition to the Mediq Own Brand product provided by Medeco, Mediq Norge have about 300 external
suppliers. Some of them are the legal Manufacturer, others are Importers or Distributors. The legal Manufactures
may have multiple production sites. Some of the production sites might be their own, while others are contracted
production sites. This results in a very large amount of productions sites. For this reason we need to prioritize
and focus our work.
For our external suppliers Mediq (Nordic cluster) has chosen to do a screening of the suppliers to focus based on
type of product. As mentioned in pt 2A1 Mediq has found that the Swedwatch report “Risk-assessments for
products within five categories: Medical supplies” represents our portfolio very well. Based on information in
this report, Mediq have identified our corresponding product categories.
In this way we have created our “Mediq High Risk List”. All suppliers that deliver products within these product
categories are flagged in this list. Medeco being one of them.
In addition Mediq has chosen to broaden the focus to include 20 of our top spend suppliers.
For our annual due diligence the prioritized suppliers are subject to further questionnaires by our third party
partner.
In 2022 this resulted in 172 selected suppliers. Covering 64% of our Nordic spend. These suppliers were requested
to answer our 2022 CSR Survey, covering the following topics:
-Ethical guidelines – implemented and distributed
-Guidelines includes UN Global Compact (principle 1-10)
-Guidelines includes the corresponding ILO Conventions
-Supply chain insight and audits
-Supply chain management and risk assessment
-Corporate management systems
-Labor and human rights
-Environment, health and safety
-Anti-corruption and bribery
The questionnaire is based on recommendations from our 3rd party CSR partner, with some amendments based
on unput from our customers and other business partners.
The results are assessed and recommendations on actions are made by our 3rd party CSR partner, in the format
of a Onepager for each supplier. The sources used is listed below*.
The Nordic Sourcing department prioritize and prepare a list of follow-up activities in a CAPA plan.
The findings and corresponding CAPAs are communicated to the Suppliers, for further dialogue to solve issues.